I didn't hear anything about any stock exchange issue.... he did however mention applying for orphan drug status for PTX100 in Europe (as I understand we only have it for US markets currently).
From the talk, I am reassured. Everything appears on track. You probably heard I asked about patent life for PTX100 as it is an asset that has been around awhile and I'm also reassured that they are working on strategy to extend this in multiple ways...
That being said... I'm really here for Omnicar... bring on that science and the publishing (when possible for IP reasons) in serious medical journals to get the doctors enthusiastic about the potential here. Bring on the first Omnicar patients!
Gav
Live Investor briefing, page-22
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
